Overview

A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors

Status:
Recruiting

Trial end date:
2024-08-01

Target enrollment:

Participant gender:

Summary

In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-M07D1. In phase Ib study, the safety and tolerability of BL-M07D1 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined. In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-M07D1 in patients

Phase:

Phase 1

Details

Lead Sponsor:

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborator:

SystImmune Inc.